IDiyas

For the Inventor, By the Inventor

Braintree, MA, United States of America

Michael Scott Visser

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 49(Granted Patents)


Location History:

  • Kent, WA (US) (2012)
  • Braintree, MA (US) (2014 - 2021)
  • Cambridge, MA (US) (2015 - 2022)
  • Briantree, MA (US) (2022)

Company Filing History:

goldMedal15 out of 3,923 
 
Novartis Ag
 patents
silverMedal2 out of 832,680 
Other
 patents

Years Active: 2012-2025

Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents
1. 12208097 - Protein kinase C inhibitors for treatment of uveal melanoma (2025-01-28),
2. 11505541 - Protein kinase C inhibitors and methods of their use (2022-11-22),
3. 11413284 - Protein kinase C inhibitors for treatment of uveal melanoma (2022-08-16),
4. 11192877 - 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2021-12-07),
5. 11059804 - Protein kinase C inhibitors and methods of their use (2021-07-13),
6. 11053218 - 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2021-07-06),
7. 10647701 - 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2020-05-12),
8. 10640489 - 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2020-05-05),
9. 10508101 - Protein kinase C inhibitors and methods of their use (2019-12-17),
10. 10414755 - 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2019-09-17),
11. 9845309 - Protein kinase C inhibitors and methods of their use (2017-12-19),
12. 9452998 - Protein kinase C inhibitors and methods of their use (2016-09-27),
13. 9181266 - 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors (2015-11-10),
14. 9126980 - Compounds for inhibiting the interaction of BCL2 with binding partners (2015-09-08),
15. 9126979 - Compounds for inhibiting the interaction of BCL2 with binding partners (2015-09-08),

Title: **Michael Scott Visser: Innovator in Targeted Cancer Therapies**

Introduction:

Michael Scott Visser is an accomplished inventor based in Braintree, Massachusetts, with a remarkable portfolio of 17 patents. His contributions primarily revolve around the field of pharmaceuticals, particularly focusing on innovative treatments for proliferative diseases such as uveal melanoma.

Latest Patents:

Visser's latest patents include groundbreaking work on Protein Kinase C (PKC) inhibitors. One prominent patent details the use of a PKC inhibitor in the treatment or prevention of proliferative diseases. This disclosure encompasses various pharmaceutical formulations and methods, offering a comprehensive approach to combating these diseases. Furthermore, he has developed pharmaceutical combinations that include PKC inhibitors along with other therapeutic agents, such as MDM2 inhibitors, demonstrating his commitment to enhancing treatment efficacy. His work on PKC inhibitors alone showcases improved efficacy at lower dosages, highlighting their potential in achieving tumor regression while maintaining gastrointestinal tolerance and enhanced kinase selectivity.

Career Highlights:

Throughout his career, Michael Scott Visser has made significant strides in the pharmaceutical industry. He has been associated with leading companies, including Novartis AG, where he helped advance various innovative therapies. His extensive experience in research and development has positioned him as a key figure in the fight against cancer.

Collaborations:

Visser has worked alongside notable colleagues, such as Simone Bonazzi and Artiom Cernijenko, fostering a collaborative environment that promotes innovative thinking and effective problem-solving. These partnerships have undoubtedly contributed to the success of his projects and patents.

Conclusion:

Michael Scott Visser exemplifies the spirit of innovation in the pharmaceutical sector. With a robust portfolio of patents focused on targeted cancer therapies, he continues to drive advancements in medical treatments. His dedication to improving patient outcomes through innovative approaches is commendable and underscores the importance of innovation in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…